DTC/DTP + Telemedicine – The Next Big Thing in Pharma?
How should pharma leaders adapt to this new DTC/DTP-driven world, and what role does telemedicine play in closing the loop from awareness to access?
DTC/DTP + Telemedicine: The Next Big Thing in Pharma?
Archbow Consulting recently partnered with Omnicom Health to raise awareness about a buzz-worthy case study examining the recent trend of Direct-to-Consumer (DTC) and Direct-to-Patient (DTP) models—and what these shifts mean for the future of the pharmaceutical industry.
Discover how DTC/DTP and telemedicine are transforming healthcare access. Dive into real-world insights on digital health solutions, improved patient outcomes, and the evolving landscape of care delivery. Read the full case study here.
For additional insights on this topic, you may also enjoy the following:
Is Your Specialty Distribution Fee Schedule Keeping Pace?
Specialty distribution fee schedules must evolve with market conditions and service requirements. Archbow provides benchmarking, FMV analysis, and negotiation support to help manufacturers establish informed, defensible agreements.
Brand Planning Season is Here: Is Patient Access Strategy at the Table?
Build patient access into 2027 brand planning to reduce therapy delays, strengthen launch readiness, and drive sustainable pharmaceutical brand growth.
Thinking Beyond the One-Size-Fits-All Approach: Choosing the Ideal 3PL Partnership
Today’s 3PL landscape offers more specialized distribution solutions than ever before. Learn how manufacturers can evaluate third-party logistics providers, align capabilities to product needs, and make informed 3PL partner decisions for a successful pharmaceutical product launch.
SUBSCRIBE
Subscribe to receive news and updates from Archbow Consulting
|
|